NCT/Study#
NCT04396860 /
NRG-BN007
A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Actively Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
DISEASE GROUP:
Neuro-Oncology
current phase:
Phase II/III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
